Access to European Union law
<a href="https://eur-lex.europa.eu/content/help/eurlex-content/experimental-features.html" target="_blank">More about the experimental features corner</a>
Choose the experimental features you want to try
EUR-Lex
Access to European Union law

This document is an excerpt from the EUR-Lex website

You are here
Use quotation marks to search for an "exact phrase". Append an asterisk (*) to a search term to find variations of it (transp*, 32019R*). Use a question mark (?) instead of a single character in your search term to find variations of it (ca?e finds case, cane, care).
Search tips
Need more search options? Use the Advanced search

Document 62012CN0493

    Kawża C-493/12: Talba għal deċiżjoni preliminari mressqa mill-High Court of Justice (Chancery Division) (ir-Renju Unit) fil- 5 ta’ Novembru 2012 — Eli Lilly and Company Ltd vs Human Genome Sciences Inc

    ĠU C 9, 12.1.2013, p. 33–33 (BG, ES, CS, DA, DE, ET, EL, EN, FR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

    12.1.2013   

    MT

    Il-Ġurnal Uffiċjali tal-Unjoni Ewropea

    C 9/33

    Talba għal deċiżjoni preliminari mressqa mill-High Court of Justice (Chancery Division) (ir-Renju Unit) fil-5 ta’ Novembru 2012 — Eli Lilly and Company Ltd vs Human Genome Sciences Inc

    (Kawża C-493/12)

    2013/C 9/55

    Lingwa tal-kawża: l-Ingliż

    Qorti tar-rinviju

    High Court of Justice (Chancery Division)

    Partijiet fil-kawża prinċipali

    Rikorrenti: Eli Lilly and Company Ltd

    Konvenuta: Human Genome Sciences Inc.

    Domandi preliminari

    (a)

    Liema huma l-kriterji li jippermettu li jiġi ddeterminat jekk “il-prodott ikun protett minn privattiva bażika fis-seħħ” fis-sens tal-Artikolu 3(a) tar-Regolament Nru 469/2009/KE (1) (iktar il-quddiem ir-“Regolament”)?

    (b)

    Dawn il-kriterji huma differenti jekk il-prodott ma huwiex prodott ta’ kombinazzjoni, u jekk iva, liema huma dawn il-kriterji?

    (c)

    Fil-każ ta’ talba dwar antikorp jew klassi ta’ antikorpi, huwa suffiċċjenti li l-antikorp jew l-antikorpi jkunu ddefiniti skont il-karatteristiċi tagħhom li jorbtuhom ma’ proteina mmirata, jew huwa neċessarju li tiġi pprovduta definizzjoni strutturatli tal-antikorp jew tal-antikorpi, u jekk iva, kemm?

    (1)  Regolament (KE) Nru 469/2009 tal-Parlament Ewropew u tal-Kunsill, tas-6 ta’ Mejju 2009, dwar iċ-ċertifikat ta’ protezzjoni supplimentari għal prodotti mediċinali (Verżjoni kodifikata) (Test b’relevanza għaż-ŻEE) ĠU L 152, p. 1.

    Top